As of 6 Nov 2026, Bharat Parenterals is loss-making on a trailing 12-month basis, so it has no P/E ratio. The share price is ₹1,881.90, 18% below its 52-week high. Sales grew 16% a year over 3 years. Debt is 0.50× equity, and its dividend yield is 0.1%. It is a small-cap company with a market cap of ₹1,297 Cr, ranked 66th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 49% over the past year.
- ₹1,850.00
- ₹1,982.80
- ₹1,793.10
- ₹1,819.00
- 5.8K
Health check
- ReturnsAhead
+48.8% over a year, better than 5 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- GrowthUnder pressure
Sales +16.4% a year over 3 years, but loss-making now.
- ProfitabilityNegative
ROCE -2.2% vs peer median 17.9%.
- Balance sheetStretched
Debt 0.50× equity, operating profit doesn’t cover interest, Piotroski 7 of 9.
- Red flags3 to check
Loss-making over the last twelve months.
Small cap
Defensive
Key metrics
- Market cap
- ₹1,297 Cr
- Small cap
- P/E
- n/a
- Industry 28.7
- Price to book
- 3.11
- Peers 4.99
- Dividend yield
- 0.05%
- ROE
- −3.0%
- Peers 14.7%
- ROCE
- −2.2%
- Peers 17.9%
- Debt to equity
- 0.50
- Debt ₹160 Cr
- EPS (TTM)
- −₹13.89
- Face value ₹10
- OPM (TTM)
- 8.4%
- Net margin 0.3%
- Sales growth
- +110.9%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 3.28
- EV/EBITDA 35.1
Strengths and risks
Strengths
- Quarterly sales up 110.9% on a year ago.
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −3.0%.
- Interest coverage of only 1.4×.
About Bharat Parenterals
Bharat Parenterals Limited engages in the research, development, manufacturing, marketing, sourcing, and distribution of pharmaceutical products in India and internationally. The company provides antibiotics, cardiovascular and central nervous system, antifungal, antimalarial, gastrointestinal tract/alimentary systems, analgesics, anaesthetics, quinolones, erectile dysfunction medicines, nutritional supplements, steroids and hormones, and other drugs. It…
- Headquarters
- Vadodara
- Employees
- 404
- Sector
- Healthcare
- ISIN
- INE365Y01019
- Website
- bplindia.in
Price range
- Avg volume (3M)
- 12K
- 1-year return
- plus 48.8%
- From 52-week high
- minus 18.0%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| BPLPHARMABharat Parenterals | 1,881.90 | plus 3.46% | 1,297 | – | 3.11 | −2.2% | −3.0% | 3.3% | 16.4% | – | 0.05% | plus 48.8% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
| ₹ Cr | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|
| 64.6 | 65.2 | 99.6 | 93.7 | 136 | |
| 63.8 | 63.4 | 100 | 85.2 | 113 | |
| 0.8 | 1.7 | −0.5 | 8.5 | 23.6 | |
| 1.3% | 2.7% | −0.5% | 9.1% | 17.3% | |
| 3.5 | 1.3 | 3.6 | 1.1 | 2.5 | |
| 3.1 | 2.9 | 2.8 | 2.5 | 3.1 | |
| 8.6 | 8.5 | 8.6 | 8.7 | 9 | |
| −7.3 | −8.3 | −8.4 | −1.5 | 14 | |
| −17.6% | −16.7% | 2.5% | −138.7% | 15.6% | |
| −7.2 | −5.3 | −4.8 | 1 | 9.4 | |
| -13.75 | -14.03 | -11.84 | 1.46 | 17.15 |
Profit & loss
- Sales CAGR 3Y
- +16.4%
- ROE
- −3.0%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 218 | 257 | 335 | 343 | |
| – | +18.1% | +30.5% | +2.3% | |
| 196 | 230 | 331 | 327 | |
| 21.6 | 27.1 | 4.4 | 15.9 | |
| 9.9% | 10.6% | 1.3% | 4.6% | |
| 9.6 | 3.2 | 9.8 | 8.1 | |
| 2.2 | 3.2 | 11.9 | 11.5 | |
| 5.9 | 9 | 35.3 | 34.3 | |
| 0.4 | 0.6 | −1 | 0.3 | |
| 23.5 | 18.7 | −34 | −21.4 | |
| 33.3% | 43.8% | −28.6% | −27.5% | |
| 16.4 | 14.5 | −12.6 | −8.2 | |
| – | minus 11.7% | minus 187.0% | – | |
| 28.40 | 24.94 | -19.26 | -11.88 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 5.8 | 5.8 | 6.9 | 6.9 | |
| 177 | 191 | 324 | 315 | |
| 49.7 | 158 | 180 | 146 | |
| 118 | 149 | 138 | 145 | |
| 350 | 504 | 649 | 613 | |
| 161 | 238 | 236 | 241 | |
| 120 | 28.3 | 37.1 | 39.7 | |
| 2.5 | 2.4 | – | 1.1 | |
| 8.9 | 8.7 | 62.6 | 6.9 | |
| 58.3 | 227 | 313 | 324 | |
| 350 | 504 | 649 | 613 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 21.7 | −4.7 | −27.3 | 38.4 | |
| −77.8 | −105 | −137 | 9.3 | |
| 60.6 | 110 | 156 | −47 | |
| 4.4 | 0.9 | −8.3 | 0.6 | |
| −91.6 | −104 | −29.1 | −39.9 | |
| −69.9 | −109 | −56.3 | −1.6 | |
| – | −0.4 | −0.6 | −0.7 |
Shareholding pattern
NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 0.1% (Yahoo estimate).
Major shareholders
Filings & events
News
No recent news coverage found.